An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) and irritable bowel syndrome (IBS) frequently co-occur, yet treating their comorbid presentation is challenging. Low-dose tricyclic antidepressants are efficacious for IBS, but higher doses to treat depressive symptoms present tolerability problems, whereas selective serotonin reuptake inhibitors are more tolerable but show inconsistent efficacy for IBS. If efficacious, serotonin-norepinephrine reuptake inhibitors like duloxetine would provide a useful alternative. We explored efficacy, tolerability, and time to onset of action of duloxetine in comorbid IBS-MDD in an open-label, 12-week trial. Repeated-measures mixed-effects regression analysis with the intent-to-treat sample assessed rate of change of the clinician-administered Gastrointestinal Symptoms Rating Scale, Montgomery-Åsberg Depression Rating Scale, and other clinician-administered and self-report scales. Seventeen Hispanic adults with current MDD and comorbid IBS meeting Rome III criteria entered the study. Medical and laboratory assessment ruled out alarm symptoms and signs inconsistent with IBS. Duloxetine led to significant improvement in Gastrointestinal Symptoms Rating Scale and Montgomery-Åsberg Depression Rating Scale scores and 71.4% and 64.3% intent-to-treat response rates for IBS and MDD, respectively. Abdominal pain severity decreased by 56%. Contrary to expectation of rapid analgesic effects, based on duloxetine studies for neuropathic pain, both IBS and MDD symptoms improved gradually; differences in slopes of improvement were nonsignificant. Duloxetine was moderately well tolerated at a mean endpoint dose of 60 mg/d. Study limitations include the lack of placebo control, modest sample size, single ethnic group, and high attrition rate. Duloxetine efficacy for comorbid IBS-MDD should be studied under placebo-controlled conditions with larger and more diverse samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There have been no RCTs of SNRIs in IBS, although there is evidence from case series that duloxetine may improve symptoms and quality of life, 224 225 and there is good evidence for use of SNRIs in other chronic painful disorders, such as fibromyalgia and low back pain.226”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [224]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200203000-00008 · Cited by 3,298
Svedlund, J., Sj�din, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,468
5-Hydroxytryptamine (serotonin) in the gastrointestinal tract
Gershon, M. D. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835bc703 · Cited by 617 · cited 1×
“Irritable bowel syndrome is often treated with antidepressants, including both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs),(1,4,5) because abnormalities in serotonergic signaling or metabolism and disturbed regulation of neurotransmission-related communication between the enter…”
BackgroundFord, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
The epidemiology of irritable bowel syndrome in North America: a systematic review1
Saito, Y. A., Schoenfeld, P., & Locke, G. R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05913.x · Cited by 548
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis
Jackson, J. L., O’Malley, P. G., Tomkins, G., Balden, E., Santoro, J., & Kroenke, K. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00299-5 · Cited by 469
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · cited 1×
“Duloxetine may successfully treat IBS symptoms and be better tolerated than TCAs due to its reduced affinity for cholinergic receptors.(11) However, no studies have explored duloxetine treatment of comorbid IBS-MDD.”
BackgroundReview article: irritable bowel syndrome
CAMILLERI, M., & CHOI, M. ‐. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.84256000.x · Cited by 290
A Multidimensional Tool to Quantify Treatment Resistance in Depression: The Maudsley Staging Method
Fekadu, A., Wooderson, S., Donaldson, C., Markopoulou, K., Masterson, B., Poon, L., & Cleare, A. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04309 · Cited by 281
Research works printed but not linked: 3
- 2001, Irritable bowel syndrome, anxiety, and depression: what are the links?, J Clin Psychiatry, 62, 38
- 2007, Antidepressants for neuropathic pain, Cochrane Database Syst Rev, 17
- 2010, A case of possible duloxetine-induced mania, Ger J Psychiatry, 13, 54
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment
Peyronnet, B., Mironska, E., Chapple, C. R., Cardozo, L., Oelke, M., Dmochowski, R. R., Amarenco, G., Gamé, X., Kirby, R. S., der Aa, F. V., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.038 · Cited by 503
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management
Staudacher, H. M., Black, C. J., Teasdale, S. B., Mikocka-Walus, A., & Keefer, L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00794-z · Cited by 249
Management of functional gastrointestinal disorders
Fikree, A., & Byrne, P. (2021) · Clinical Medicine · doi:10.7861/clinmed.2020-0980 · Cited by 179
Opioid misuse in gastroenterology and non-opioid management of abdominal pain
Szigethy, E., Knisely, M., & Drossman, D. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.141 · Cited by 117
Metadata
- Authors
- Lewis-Fernández, R., Lam, P., Lucak, S., Galfalvy, H., Jackson, E., Fried, J., Rosario, M., de la Cruz, A. A., Sánchez-Lacay, A., Díaz, S., & Schneier, F.
- Affiliations
- From the *Department of Psychiatry, Columbia University; †New York State Psychiatric Institute; and ‡Weill Cornell Medicine, New York, NY.
- Weill Cornell Medicine (US)
- Corresponding author
- Galfalvy, Hanga
- Fried, Jane
- Sánchez-Lacay, Arturo
- Schneier, Franklin
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2016-12
- Volume
- 36
- Issue
- 6
- Pages
- 710-715
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2537475627
- Cited by
- 49
- References
- 19
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 11 · 2020: 7 · 2019: 4 · 2018: 2 · 2017: 2
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- duloxetine, irritable bowel syndrome, major depressive disorder, comorbidities, serotonin-norepinephrine reuptake inhibitors, abdominal pain, antidepressant tolerability, onset of action, Hispanic adults, Rome III criteria
- MeSH terms
- Duloxetine Hydrochloride, Serotonin and Noradrenaline Reuptake Inhibitors, Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Severity of Illness Index, Abdominal Pain, Treatment Outcome, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0000000000000599
- The paper
- Lewis-Fernández, R., Lam, P., Lucak, S., Galfalvy, H., Jackson, E., Fried, J., Rosario, M., de la Cruz, A. A., Sánchez-Lacay, A., Díaz, S., & Schneier, F. (2016). An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000599
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.